



## Characterization of Novel Amyloid- $\beta$ Peptide ( $A\beta$ ) Binding Ligands

Silke Dornieden

Forschungszentrum Jülich GmbH  
Institute of Complex Systems (ICS)  
Strukturbiochemie (ICS-6)

# Characterization of Novel Amyloid- $\beta$ Peptide ( $A\beta$ ) Binding Ligands

Silke Dornieden

Schriften des Forschungszentrums Jülich  
Reihe Gesundheit / Health

Band / Volume 61

---

ISSN 1866-1785

ISBN 978-3-89336-844-0

# Table of contents

<b>Table of figures</b> .....	<b>iv</b>
<b>Index of tables</b> .....	<b>vi</b>
<b>1 Introduction</b> .....	<b>1</b>
1.1 Alzheimer's disease (AD).....	1
1.2 Pathology of AD .....	2
1.3 Amyloid- $\beta$ .....	3
1.3.1 Processing of the amyloid precursor protein (APP) to A $\beta$ .....	3
1.3.2 Amyloid- $\beta$ peptide (A $\beta$ ) and its aggregation pathway.....	4
1.3.3 Amyloid cascade hypothesis.....	6
1.4 Diagnosis of AD .....	8
1.5 Therapy of AD .....	9
1.5.1 Immunotherapy and single chain variable fragments (scFv).....	11
1.5.2 Therapy with peptides.....	15
1.5.3 D1, V1 and D3 .....	16
1.6 Project Aims .....	18
<b>2 Materials and Methods</b> .....	<b>19</b>
2.1 Materials .....	19
2.1.1 Chemicals, buffers and media.....	19
2.1.2 Cells and plasmids .....	20
2.1.3 Molecular weight markers .....	21
2.1.4 Antibodies, enzymes and peptides.....	22
2.1.5 Kits.....	24
2.1.6 Materials, laboratory equipment and software.....	24
2.2 Methods .....	26
2.2.1 Molecular biology methods .....	26
2.2.1.1 Preparation of plasmid DNA.....	26
2.2.1.2 Determination of the DNA concentration .....	26
2.2.1.3 Sequencing of plasmid DNA.....	26
2.2.1.4 Agarose gel electrophoresis .....	27
2.2.1.5 Purification of DNA from gel electrophoresis .....	27
2.2.1.6 Restriction digestion of plasmid DNA .....	27
2.2.1.7 Dephosphorylation and ligation of DNA fragments .....	28
2.2.1.8 Transformation of <i>E. coli</i> with plasmid DNA.....	28
2.2.2 Expression and purification of proteins .....	28
2.2.2.1 SDS polyacrylamide gel electrophoresis.....	28
2.2.2.2 Protein concentration determination .....	29

2.2.2.3	Expression of single-chain variable fragments .....	30
2.2.2.4	Purification of single-chain variable fragments .....	30
2.2.2.5	Expression of A $\beta$ 1-16-GB1.....	32
2.2.2.6	Purification of A $\beta$ 1-16-GB1 .....	32
2.2.3	Coupling of A $\beta$ 1-16-GB1 to NHS-activated sepharose .....	33
2.2.4	A $\beta$ preparations.....	34
2.2.4.1	Monomerization of A $\beta$ .....	34
2.2.4.2	Preparation of A $\beta$ monomers, oligomers and fibrils .....	34
2.2.4.3	Concentration determination of A $\beta$ samples.....	34
2.2.5	Biochemical and biophysical methods .....	35
2.2.5.1	Nuclear magnetic resonance (NMR) spectroscopy .....	35
2.2.5.2	Surface plasmon resonance (SPR) spectroscopy .....	35
2.2.5.3	Dynamic light scattering (DLS) .....	39
2.2.5.4	Western blot .....	39
2.2.5.5	Enzyme-linked immunosorbent assay (ELISA).....	40
2.2.5.6	Thioflavin T assay.....	41
2.2.6	Cell culture.....	42
2.2.6.1	Cultivation of cells .....	42
2.2.6.2	Cell counting .....	42
2.2.6.3	MTT assay.....	43
<b>3</b>	<b>Results .....</b>	<b>44</b>
3.1	Single-chain variable fragments .....	44
3.1.1	Expression and purification of A $\beta$ 1-16-GB1 .....	44
3.1.2	Expression and purification of scFv-IC16 and mutants.....	47
3.1.2.1	Recloning of scFvs .....	47
3.1.2.2	Expression of scFvs.....	48
3.1.2.3	Purification of scFvs.....	48
3.1.3	NMR experiments with scFv-IC16.....	52
3.1.4	Characterization of the binding affinity of scFvs to different N-terminal A $\beta$ peptides by SPR.....	54
3.1.5	ELISA and dot blot detection of different A $\beta$ conformers .....	62
3.1.6	Influence of scFv-IC16 on A $\beta$ 1-42 fibrilization .....	67
3.2	Studies of novel D-peptides .....	70
3.2.1	<i>In vitro</i> binding of the novel D-peptides to different A $\beta$ conformers .....	70
3.2.2	Influence of the novel D-peptides on the fibrilization process of A $\beta$ 1-42.....	73
3.2.3	Influence of the novel D-peptides on the particle size of A $\beta$ 1-42.....	79
3.2.4	Influence of the novel D-peptides on the cell viability in the presence of A $\beta$ .....	82
<b>4</b>	<b>Discussion .....</b>	<b>86</b>
4.1	Single-chain variable fragments in AD therapy .....	86
4.1.1	Comparison of the CDR sequences of scFv-IC16 to already existing anti A $\beta$ antibodies or antibody fragments showed high similarity to PFA 1.....	87

---

4.1.2	Rational design of scFv-IC16 variants was partly successful.....	92
4.1.3	N-terminal biotin tag shows steric hindrance in ELISA experiments .....	93
4.1.4	Both mAB-IC16 and scFv-IC16 inhibit the development of ThT positive A $\beta$ fibrils.....	97
4.2	Characteristics of novel D-peptides .....	99
4.2.1	D1 and D3 – a base for novel D-peptides.....	99
4.2.2	Novel D-peptides show higher affinity towards monomers and oligomers .....	101
4.2.3	Novel D-peptides lead to larger, ThT negative aggregates .....	102
4.2.4	Novel D-peptides influence the cell viability.....	104
4.2.5	Advantages of the novel D-peptides – a possible mode of action.....	105
4.3	scFvs and D-peptides – a comparison.....	106
4.4	Prospective.....	107
	<b>Summary .....</b>	<b>108</b>
	<b>Zusammenfassung.....</b>	<b>109</b>
	<b>Appendix .....</b>	<b>110</b>
	Abbreviations .....	110
	One letter code of amino acids .....	112
	List of awards, publications and posters.....	113
	References .....	115
	Acknowledgements .....	128
	Erklärung .....	130



**Gesundheit / Health**  
**Band / Volume 61**  
**ISBN 978-3-89336-844-0**

 **JÜLICH**  
FORSCHUNGSZENTRUM